GlassScriptPhysician profile
Uyen Dinh
NPI 1568870145
$19,954.14
in general payments reported to CMS, 2019-2025
19 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $3,583 · 2023: $13K · 2024: $1,652 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,763 · Food and Beverage: $4,810 · Travel and Lodging: $1,456 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,762.50 |
| Food and Beverage | $4,810.15 |
| Travel and Lodging | $1,455.77 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,670.88 | 2022-2025 | |
| Alkermes, INC. | $1,032.16 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,003.54 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $923.44 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $870.19 | 2023-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $389.80 | 2023-2025 | Auvelity |
| Abbott Laboratories | $217.12 | 2024 | Eterna |
| Supernus Pharmaceuticals, INC. | $176.07 | 2023-2024 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $139.71 | 2022-2023 | Uzedy |
| Ironshore Pharmaceuticals INC. | $101.00 | 2024 | |
| Sunovion Pharmaceuticals INC. | $99.12 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.89 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $71.72 | 2021-2022 | |
| Amgen INC. | $53.42 | 2022 | |
| Corium, LLC | $41.01 | 2025 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $27.61 | 2021 | |
| Noven Therapeutics, LLC | $19.12 | 2025 | Secuado, Xelstrym |
| Neurocrine Biosciences, INC. | $18.37 | 2025 | |
| Lundbeck LLC | $15.97 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uyen Dinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.